Skip to content
Surprise PRP Guide
A date-stamped guide to platelet-rich plasma research

Surprise PRP Guide

What do people in Surprise ask about PRP?

A sore joint can raise the same questions each morning. PRP means platelet rich plasma, prepared by separating a platelet-heavy part of your blood. The answers below cover what people often ask before a clinic visit. Your exam and health history still decide which care may fit.

Does PRP work for every sore joint?

No single answer fits every joint or every cause of soreness. A knee result may say little about a shoulder, hip, or tendon. Some people report better movement, while some careful studies find little change. Ask whether the research matches your sore area and daily needs.

How is PRP prepared?

Clinic staff draw a small amount of your blood. The machine divides it, and staff keep the platelet-heavy portion. Staff then use that concentrated part where the soreness starts. Ask how the clinic prepares it and what you may feel afterward.

What may make PRP a poor fit?

An active infection, a blood problem, certain medicine, or severe joint damage may change the choice. Don’t stop blood thinners or other prescribed medicine on your own. The provider needs your health history and an exam before discussing whether PRP may fit.

What are common PRP side effects?

Soreness and swelling can occur after the procedure, and they are usually short lived. Infection and other problems are less common but need clear instructions. Ask which symptoms are expected, whom to call, and when urgent care is needed.

Does insurance cover PRP?

Coverage is often limited for joint or tendon care. Medicare has a narrow national policy, while private insurance depends on the plan. Ask the clinic for a written price, then call your insurer. A verbal estimate can miss follow-up or separate fees.

What can I try before PRP?

Gentle exercise, paced activity, a well-fitted brace, or medicine may help, depending on the cause. Your own doctor or nurse can help choose safe home care. Keep notes on what you tried, how long you tried it, and what changed.

Sources

  1. The American Academy of Physical Medicine and Rehabilitation convened a technical expert panel that ran a structured literature review (2023, updated through June 2025) and a modified Delphi process, and issued five evidence-based clinical recommendations plus 11 consensus-based best practices for PRP in knee osteoarthritis. The statement is explicit that orthobiologic therapies 'remain an evolving area of practice' and that robust, dose-dependent randomized controlled trials are still needed to establish PRP's clinical effects.

    Borg-Stein J, Jayaram P, Colorado BS, et al. — AAPM&R guidance statement on platelet rich plasma for knee osteoarthritis. PM&R, 2026. DOI: 10.1002/pmrj.70144.

  2. A Bayesian network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 trials, 22,795 participants, 18 intra-articular interventions) found treatment effects were larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. Excluding high-risk trials, the effects of 16 of the 18 intra-articular interventions in knee or hip OA were smaller than the minimal clinically important difference and most were consistent with placebo effects; triamcinolone had the highest probability of exceeding the MID at weeks 2-6.

    Pereira TV, Saadat P, Bobos P, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

  3. A meta-analysis of 73 articles covering 5,895 patients quantified the PLACEBO response to intra-articular injection in knee osteoarthritis: statistically and clinically significant improvements in pain, function and quality of life at 1, 3 and 6 months, with responder rates above 50% at each of those points, declining by 12 months. The placebo response was stronger in trials with more female participants and in more recently published trials. This is why an uncontrolled 'our patients improved' figure carries almost no information.

    Previtali D, Boffa A, Di Laura Frattura G, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Reviews, 2025. DOI: 10.1530/EOR-2025-0022.

  4. A systematic review of 29 randomized trials of PRP for knee OA that reported a platelet count, concentration or dose found that the 28 treatment arms with statistically significant positive outcomes at 6 months had a mean platelet dose of 5,500 (+/-474) x 10^6, while the three arms without a positive difference averaged 2,302 (+/-437) x 10^6 (P<.01). The same separation held at 12 months: 5,464 versus 2,253 x 10^6 (P<.05).

    Berrigan WA, Bailowitz Z, Park A, et al. — A Greater Platelet Dose May Yield Better Clinical Outcomes for Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Systematic Review. Arthroscopy, 2025. DOI: 10.1016/j.arthro.2024.03.018.

  5. A systematic review and meta-analysis of platelet dosage across musculoskeletal conditions identified a potential dose-response relationship in knee osteoarthritis, with an apparent threshold above 10 billion platelets for favourable clinical outcomes, and the effect more pronounced for function than for pain. For conditions other than knee OA the authors found the literature too unclear to identify an optimal dose.

    Berrigan W, Tao F, Kopcow J, et al. — The Effect of Platelet Dose on Outcomes after Platelet Rich Plasma Injections for Musculoskeletal Conditions: A Systematic Review and Meta-Analysis. Current Reviews in Musculoskeletal Medicine, 2024. DOI: 10.1007/s12178-024-09922-x.

  6. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development clinical study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient as cash-pay.

    Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

  7. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

    U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.

Talk through the soreness and the choices

At the first visit, licensed clinic staff examine the sore area and review your health history. They can explain available PRP choices, likely cost, and what to expect afterward.

The nearby Peoria office is at 13128 N. 94th Dr., Suite 205, Peoria, AZ 85381. Call (602) 837-PAIN to confirm current scheduling and directions.

Book a free consultation